Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions


Journal Article

Full Text

Duke Authors

Cited Authors

  • Pollack, C; Reilly, PA; Verhamme, P; Bernstein, R; Dubiel, R; Eikelboom, J; Huisman, M; Hylek, E; Kam, C-W; Kamphuisen, PW; Kreuzer, J; Levy, JH; Sellke, F; Steiner, T; Wang, B; Weitz, J

Published Date

  • June 1, 2015

Published In

Volume / Issue

  • 13 /

Start / End Page

  • 85 - 85

Published By


  • 1

Electronic International Standard Serial Number (EISSN)

  • 1538-7836

International Standard Serial Number (ISSN)

  • 1538-7933


  • English